A director at Solvay SA bought 1,083 shares at 27.740EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...
We upgrade our 2026 Bimzelx sales to be €0.9bn higher than consensus with conservative assumptions & and are now 11% above consensus on 2026 group sales & 19% on EBITDA. We upgrade our already above-consensus ‘27 EBITDA by 5%. Using our proprietary product-by-product Contribution Analysis, we show that the gross margin is highly sensitive to Bimzelx growth. We analyse the galvokimig data, which looks very strong Vs Dupi. Whilst UCB pipeline readouts & Moonlake risk will dominate specialists’ tho...
UCB's growth continues with 1H25 earnings increasing to € 3.49b, beating CSS expectations by approx. 8%. We note that Bimzelx performed significantly higher vs. expectations bringing in € 799m (CSS: € 615m) continuing its solid growth momentum. The company updated its FY25 guidance to revenue of at least € 7b based on a strong outlook for the remainder of the year. We reiterate our €214 TP and Accumulate.
AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...
Below are the key highlights from the conference call. Solvay's 1Q25 uEBITDA dropped 15% to € 230m, in line with the recent profit warning. Solvay reiterated the (recently cut) FY25 underlying EBITDA guidance of € 880-930m (c. -12% at midpoint vs the previous € 1.0-1.05bn range), citing continued soft demand in a context of tariff and geopolitical uncertainty. Solvay had already stated to maintain FCF guidance of c. € 300m (on the back of more prudent capex spending) which however still means th...
Aedifica: Strong results, guidance reiterated; dsm-firmenich: Symrise 1H25 results; IMCD: Stagnating gross profit leads to disappointing 2Q25 EBITA; JDE Peet's: Full of beans; Just Eat Takeaway: 1H25 results, weak update no impact on takeover; Lotus Bakeries: Peer Mondelez 1Q25 results; Melexis: 2Q25 results, gross margin under pressure; Solvay: 2Q25 in line, subdued outlook no surprise after pre-release; TKH Group: Preview: Under a magnifying glass; Universal Music Group: Spotify 2Q25 ...
Solvay's 1Q25 uEBITDA dropped 15% to € 230m, in line with the recent profit warning. Solvay reiterated the (recently cut) FY25 underlying EBITDA guidance of € 880-930m (c. -12% at midpoint vs the previous € 1.0-1.05bn range), citing continued soft demand in a context of tariff and geopolitical uncertainty. Solvay had already stated to maintain FCF guidance of c. € 300m (on the back of more prudent capex spending) which however still means that almost all FCF is absorbed to pay the high and commi...
Solvay second quarter 2025 results Press release Regulated information Continued solid EBITDA margin and Free cash flow delivery, despite soft demand environment Brussels, July 30, 2025, 7.00am CEST Highlights Underlying net sales in Q2 2025 of €1,102 million were down -3.8% organically compared to Q2 2024 due to the soft market environment, impacted by ongoing tariff and geopolitical tensions. This resulted in a continued reduction of short term demand, particularly visible in certain soda ash and Coa...
Solvay : résultats du deuxième trimestre 2025 Communiqué de presse Information réglementée Marge d’EBITDA et génération de Free Cash Flow toujours solides, malgré un contexte de demande modérée Bruxelles, le 30 juillet 2025 à 7h00 CEST Faits marquants Le chiffre d'affaires sous-jacent du T2 2025 s'est établi à €1 102 millions, en baisse de -3,8% en organique par rapport au T2 2024, en raison d'un environnement de marché morose, affecté par les tensions tarifaires et géopolitiques persistantes. Cela s'est traduit par une baisse continue de la demande à court terme, particulièr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.